Isabelle Rivière

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

62h-index25.9kcitations298works4.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(214), Virus-based gene therapy research(56), Immunotherapy and Immune Responses(43), CRISPR and Genetic Engineering(41), Immune Cell Function and Interaction(36)

Publications298 total

iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches
Advanced Drug Delivery Reviews·2025· 4 citedOpen Access
Overcoming barriers to commercially pre-viable gene and cell therapies for rare and ultra-rare diseases
Molecular Therapy·2025· 4 citedOpen Access
Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies
Blood Advances·2025· 13 citedOpen Access
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma
Journal of Clinical Oncology·2025· 9 citedOpen Access
Phase I Trial of MCARH109, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis
Journal of Clinical Oncology·2024· 17 citedOpen Access
Optimizing Therapeutic Outcome of CD19(T2)28z1XX Chimeric Antigen Receptor (CAR) T in Adult Patients with Large B-Cell Lymphoma through a Quantitative Medicine Approach
Blood·2024
CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia
Blood·2024· 7 citedOpen Access
Les cellules CAR-T anti-CD19 : prototypes du médicament vivant
Bulletin de l Académie Nationale de Médecine·2024
P-038 Phase I Trial of MCARH109, a First-in-Class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T-cell Therapy for Relapsed or Refractory Multiple Myeloma: Updated Analysis
Clinical Lymphoma Myeloma & Leukemia·2024· 2 cited
Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell Lymphoma
2024· 2 citedOpen Access
Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors
Nature Biotechnology·2024Open Access
Author Correction: Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells
Nature Biomedical Engineering·2024· 1 citedOpen Access
Long Term Follow-up after Treatment with Allogeneic Off-the-Shelf CAR T Cell Therapy for Relapsed or Refractory B-Cell Malignancies
Blood·2023· 5 cited
A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Blood·2023· 4 cited
A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2
Blood·2023· 2 cited
Role of Cell Therapy Product Characteristics in Patient Response to TAK-940 (CD19(T2)28z1xx Chimeric Antigen Receptor (CAR) T): Biomarker Analyses from a Phase I Study in Adult Patients with Relapsed or Refractory B-Cell Malignancies
Blood·2023Open Access
Cooperative CAR targeting to selectively eliminate AML and minimize escape
Cancer Cell·2023· 93 citedOpen Access
S104: DIFFERENTIAL TARGET PROFILES AND EFFICACY OF ADCLEC.SYN1 AND CD33-CARS IN HUMANIZED AML MODELS
HemaSphere·2023· 2 citedOpen Access
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
Nature Medicine·2023· 144 citedOpen Access
Validation of a High-Sensitivity Assay for Detection of Chimeric Antigen Receptor T-Cell Vectors Using Low-Partition Digital PCR Technology
Journal of Molecular Diagnostics·2023· 2 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Michel Sadelain(37), Renier J. Brentjens(26), Xiuyan Wang(13), Jae H. Park(12), Brigitte Sénéchal(9), Yvette Bernal(8), Elizabeth Halton(7), Terence J. Purdon(7), Kevin J. Curran(6), Craig S. Sauter(5), Yongzeng Wang(5), Bianca Santomasso(5), Marco L. Davila(5), Jolanta Stefanski(5), Sergio Giralt(5), Eric L. Smith(5), Miguel‐Angel Perales(5), Mithat Gönen(4), Elena Mead(4), P. Maslak(4)